The Latest Cardiac and Vascular News
LEVALLOIS-PERRET, France–(BUSINESS WIRE)–Cardiawave, a pioneering medtech company developing non-invasive ultrasound therapy (NIUT) for aortic stenosis, has received CE Certificate for Valvosoft®, the world’s first non-invasive therapeutic alternative to treat Severe Symptomatic Aortic Stenosis (sSAS), a serious, degenerative and fast-growing disease due to population aging, which remains without a solution for […]
PARIS & BOSTON–(BUSINESS WIRE)–Cardiawave, a pioneering medtech company developing non-invasive ultrasound therapy (NIUT) for aortic stenosis, today announced the appointment of Jonathan Freeman, PhD, as Chairman of its Board of Directors. This marks a key milestone in the company’s evolution, reinforcing its ambition to set new frontiers in the treatment of […]
WASHINGTON–(BUSINESS WIRE)–Cardiawave SA, developer of the groundbreaking Valvosoft Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis (CAS), today announced that the device met the primary endpoint in its pivotal study and improved or stabilized heart failure symptoms for 80.5% of patients, substantially improving hemodynamics […]
April 16, 2024 07:24 AM Eastern Daylight Time LEVALLOIS-PERRET, France–(BUSINESS WIRE)–Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as its new Chief Executive Officer. […]
LEVALLOIS-PERRET, France–(BUSINESS WIRE)–Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft®, an innovative non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, announces the issuance of 3 new patents in the United States. These patents protect Valvosoft®’s ultrasound imaging and therapy device […]
– No cerebral vascular anomaly before and after treatment observed – Successful completion of the FIM II clinical study prior to the pivotal study, that will pave the way for CE marking PARIS–(BUSINESS WIRE)–Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic […]
PARIS–(BUSINESS WIRE)–Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced the authorization by the French National Agency for the Safety of Medicines and Health Products to proceed with a […]
The trial with VALVOSOFT® its disruptive, non-invasive, ultrasound treatment was proven to: be safe and feasible provide a sustained repair of the aortic valve improve quality of life of the 34 patients treated PARIS–(BUSINESS WIRE)–Cardiawave SA, a deeptech medical device company that has developed VALVOSOFT® a revolutionary non-invasive medical device to […]
Paris, November 17th, 2020 The French MedTech Cardiawave has been granted authorization by the Agence Nationale de Sécurité du Médicament et des produits de santé – ANSM (French National Agency for Health Products Safety) on October 20th to extend its clinical trial in France and treat patients with calcific aortic […]
